The Dow Jones rose Friday on strong Apple earnings and key inflation data, while Deckers stock plunged on earnings results.

Stock futures are higher Friday morning as investors respond to a steady stream of earnings reports and await the release of a closely followed inflation indicator.

Stock futures are mixed Thursday morning as investors react to a barrage of earnings reports from major companies and important economic indicators.

P&G is a unique Dividend King because it uses both buybacks and dividends to return capital to shareholders. A Dividend King like Coca-Cola may yield more than P&G, but it doesn't consistently buy back stock.

SP500 gains ground despite the weaker-than-expected GDP Growth Rate report. The report showed that GDP Growth Rate declined from 3.1% to 2.3%, compared to analyst consensus of 2.6%. Initial Jobless Claims report showed that 207,

Eight of the 30 Dow components lost value in 2024. Here's a quick look at each company, to help you determine which dividend stocks stand out as the best buys right now.

S&P 500 futures rise as Meta and Tesla gain, but Microsoft and Caterpillar drag the Dow. US stock market reacts to earnings, GDP data, and Fed outlook.

In addition to Olay, P&G said it is innovating in core brands like Pantene and Head and Shoulders, and saw 5% growth in P&G-owned Japanese luxury skincare brand, SK II. P&G attributed the strong performance of SK II to brand building and improved sentiment in China toward Japanese brands.

Good news about an experimental weight-loss shot sent shares in Ozempic maker Novo Nordisk soaring, making it once again Europe's most-valuable listed company. A pullback in the Danish drug maker's shares had meant it recently ceded that title to French luxury conglomerate LVMH.

U.S. stocks opened higher on Friday after an earnings report from Apple impressed investors by showing strong growth in the consumer-tech giant's services business. Later, a reading from the Federal Reserve's preferred inflation gauge,

The pharma major beat analysts' expectations in the fourth quarter of 2024, despite looming competition for its top heart drug Entresto. The watchdog blocked access to DeepSeek after the companies that provide the chatbot service allegedly failed to provide it with information about personal data collected.